nintedanib — CareFirst (Caremark)
Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Initial criteria
- Diagnosis of systemic sclerosis-associated interstitial lung disease confirmed by a high-resolution computed tomography (HRCT) study of the chest.
Reauthorization criteria
- Member is currently receiving treatment with Ofev.
Approval duration
12 months